Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Juliana Choza"'
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 12, Iss 4, Pp 1636-1651 (2022)
SARS-CoV-2 main protease (Mpro) is one of the most extensively exploited drug targets for COVID-19. Structurally disparate compounds have been reported as Mpro inhibitors, raising the question of their target specificity. To elucidate the target spec
Externí odkaz:
https://doaj.org/article/90e935f2a53a452db3183c1acd1643a3
Publikováno v:
Acta Pharmaceutica Sinica. B
SARS-CoV-2 main protease (Mpro) is one of the most extensively exploited drug targets for COVID-19. Structurally disparate compounds have been reported as Mpro inhibitors, raising the question of their target specificity. To elucidate the target spec
Autor:
Haozhou Tan, Xiangzhi Meng, Maura V Gongora, Michael Dominic Sacco, Fushun Zhang, Yanmei Hu, Yan Xiang, Zilei Xia, Yu Chen, Juliana Choza, Janice Jang, Michael T. Marty, Chunlong Ma, Jun Wang, Julia Alma Townsend, Xiujun Zhang
Publikováno v:
Journal of the American Chemical Society
The main protease (Mpro) is a validated antiviral drug target of SARS-CoV-2. A number of Mpro inhibitors have now advanced to animal model study and human clinical trials. However, one issue yet to be addressed is the target selectivity over host pro
Publikováno v:
ACS infectious diseases. 8(5)
The global COVID-19 pandemic underscores the dire need for effective antivirals. Encouraging progress has been made in developing small-molecule inhibitors targeting the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) and main protease (M
The global COVID-19 pandemic underscores the dire need of effective antivirals. Encouraging progress has been made in developing small molecule inhibitors targeting the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) and main protease (Mpro). However,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c708781413a7e43601c937f29628de83
https://doi.org/10.1101/2021.12.02.471030
https://doi.org/10.1101/2021.12.02.471030